DK1981863T3 - Fremgangsmåde til fremstilling af aminocrotonylaminosubtituerede quinazolinderivater - Google Patents

Fremgangsmåde til fremstilling af aminocrotonylaminosubtituerede quinazolinderivater

Info

Publication number
DK1981863T3
DK1981863T3 DK07704145.7T DK07704145T DK1981863T3 DK 1981863 T3 DK1981863 T3 DK 1981863T3 DK 07704145 T DK07704145 T DK 07704145T DK 1981863 T3 DK1981863 T3 DK 1981863T3
Authority
DK
Denmark
Prior art keywords
aminocrotonylaminosubstituted
preparation
quinazoline derivatives
quinazoline
derivatives
Prior art date
Application number
DK07704145.7T
Other languages
English (en)
Inventor
Juergen Schroeder
Georg Dziewas
Thomas Fachinger
Burkhard Jaeger
Carsten Reichel
Svenja Renner
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK1981863T3 publication Critical patent/DK1981863T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D293/00—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms
    • C07D293/02—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms not condensed with other rings
    • C07D293/04—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DK07704145.7T 2006-01-26 2007-01-25 Fremgangsmåde til fremstilling af aminocrotonylaminosubtituerede quinazolinderivater DK1981863T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06100914 2006-01-26
PCT/EP2007/050752 WO2007085638A1 (en) 2006-01-26 2007-01-25 Process for preparing aminocrotonylamino-substituted quinazoline derivatives

Publications (1)

Publication Number Publication Date
DK1981863T3 true DK1981863T3 (da) 2013-01-02

Family

ID=38180518

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07704145.7T DK1981863T3 (da) 2006-01-26 2007-01-25 Fremgangsmåde til fremstilling af aminocrotonylaminosubtituerede quinazolinderivater

Country Status (11)

Country Link
US (3) US7960546B2 (da)
EP (1) EP1981863B1 (da)
JP (1) JP5241513B2 (da)
CA (1) CA2639936C (da)
CY (1) CY1113778T1 (da)
DK (1) DK1981863T3 (da)
ES (1) ES2397181T3 (da)
PL (1) PL1981863T3 (da)
PT (1) PT1981863E (da)
SI (1) SI1981863T1 (da)
WO (1) WO2007085638A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71976C2 (en) 1999-06-21 2005-01-17 Boehringer Ingelheim Pharma Bicyclic heterocycles and a medicament based thereon
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US7197160B2 (en) 2001-03-05 2007-03-27 Digimarc Corporation Geographic information systems using digital watermarks
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de) * 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
EP3173084B1 (en) 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
DK1948180T3 (da) * 2005-11-11 2013-05-27 Boehringer Ingelheim Int Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
US7960546B2 (en) 2006-01-26 2011-06-14 Boehringer Ingelheim International Gmbh Process for preparing aminocrotonylamino-substituted quinazoline derivatives
ES2385613T3 (es) 2006-09-18 2012-07-27 Boehringer Ingelheim International Gmbh Método para tratar cánceres que portan mutaciones de EGFR
PE20100252A1 (es) * 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
AU2010266725A1 (en) * 2009-07-02 2012-02-23 Newgen Therapeutics, Inc. Phosphorus containing quinazoline compounds and methods of use
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
EP2608792B1 (en) 2010-08-26 2017-10-11 Boehringer Ingelheim International GmbH Methods of administering an egfr inhibitor
KR20200003933A (ko) 2011-03-04 2020-01-10 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
WO2013013640A1 (zh) * 2011-07-27 2013-01-31 上海医药集团股份有限公司 喹唑啉衍生物、其制备方法、中间体、组合物及其应用
WO2014012859A1 (en) 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof
US20150368230A1 (en) * 2013-02-01 2015-12-24 Boehringer Ingelheim International Gmbh Radiolabeled quinazoline derivatives
US9556191B2 (en) 2013-04-28 2017-01-31 Sunshine Lake Pharma Co., Ltd. Aminoquinazoline derivatives and their salts and methods of use thereof
WO2014180271A1 (zh) * 2013-05-10 2014-11-13 苏州明锐医药科技有限公司 阿法替尼及其中间体的制备方法
CN103254183B (zh) * 2013-05-10 2015-11-11 苏州明锐医药科技有限公司 阿法替尼的制备方法
CN103254156B (zh) * 2013-05-10 2015-08-26 苏州明锐医药科技有限公司 阿法替尼中间体的制备方法
CN103288808B (zh) * 2013-05-16 2015-11-11 苏州明锐医药科技有限公司 一种阿法替尼的制备方法
CN104710413B (zh) * 2013-12-16 2019-05-03 江苏豪森药业集团有限公司 二马来酸阿法替尼的制备方法
US9242965B2 (en) * 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN104151359A (zh) * 2014-07-15 2014-11-19 杭州华东医药集团新药研究院有限公司 喹唑啉类化合物及其制备方法和在制备酪氨酸激酶抑制剂中的应用
CN105315263B (zh) * 2014-07-30 2018-11-27 正大天晴药业集团股份有限公司 阿法替尼中间体的合成方法
CN105439879B (zh) * 2014-08-07 2018-08-10 天津法莫西医药科技有限公司 一种反式-4-二甲胺基巴豆酸盐酸盐的制备方法
CN105330652B (zh) * 2014-08-07 2019-04-05 天津法莫西医药科技有限公司 一种阿法替尼的制备方法
CN104447713B (zh) * 2014-11-18 2019-03-29 江苏奥赛康药业股份有限公司 阿法替尼化合物的制备方法
EP3023421A1 (en) 2014-11-21 2016-05-25 Sandoz Ag Crystalline forms of afatinib dimaleate
CN105777655B (zh) * 2014-12-25 2018-02-02 深圳海王医药科技研究院有限公司 萘普替尼对甲苯磺酸盐的α晶型及制备方法和含有其的药物组合物
CN104592212B (zh) * 2014-12-31 2017-11-10 广东东阳光药业有限公司 一种阿法替尼中间体的制备方法
CN105175400B (zh) * 2015-09-29 2018-04-10 河北神威药业有限公司 一种阿法替尼中间体的制备方法
KR20180086187A (ko) 2015-10-05 2018-07-30 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료
CN107216317B (zh) * 2016-03-21 2020-04-07 上海医药工业研究院 一种阿法替尼中间体的制备方法
CN105669658B (zh) * 2016-04-05 2018-06-29 北京民康百草医药科技有限公司 一种阿法替尼的精制方法
CN106045983A (zh) * 2016-06-02 2016-10-26 苏州富士莱医药股份有限公司 阿法替尼的制备方法
CN107488171B (zh) * 2016-06-10 2020-08-28 山东新时代药业有限公司 一种阿法替尼制备方法
CN105968103B (zh) * 2016-07-18 2018-11-27 山东罗欣药业集团恒欣药业有限公司 抗肿瘤药物阿法替尼的合成方法
CN106243092B (zh) * 2016-07-28 2019-02-15 南京臣功制药股份有限公司 一种高选择性制备马来酸阿法替尼的方法
CN106565692A (zh) * 2016-11-03 2017-04-19 常茂生物化学工程股份有限公司 一种阿法替尼合成工艺的改进方法
CN106908531B (zh) * 2017-02-22 2019-08-06 深圳海王医药科技研究院有限公司 一种高效液相色谱梯度法同时测定萘普替尼光降解产物及其它有关物质的方法
CN110693846B (zh) * 2018-07-10 2021-07-27 杭州华东医药集团新药研究院有限公司 迈华替尼药物组合物及其制备方法
CN110590754A (zh) * 2019-09-21 2019-12-20 广东安诺药业股份有限公司 一种马来酸阿法替尼中间体的制备方法
JP7450037B2 (ja) 2020-07-09 2024-03-14 Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａ株式会社 脳転移を有する末期非小細胞肺がん患者を治療するための組み合わせ医薬品
WO2023028056A1 (en) 2021-08-24 2023-03-02 Genentech, Inc. 3-amino piperidyl sodium channel inhibitors
IL313670A (en) 2021-12-30 2024-08-01 Biomea Fusion Inc Pyrazine compounds as inhibitors of FLT3

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71976C2 (en) 1999-06-21 2005-01-17 Boehringer Ingelheim Pharma Bicyclic heterocycles and a medicament based thereon
DE10063435A1 (de) * 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20030225079A1 (en) 2002-05-11 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
DE10307165A1 (de) * 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP3173084B1 (en) 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
DK1948180T3 (da) 2005-11-11 2013-05-27 Boehringer Ingelheim Int Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
US7960546B2 (en) 2006-01-26 2011-06-14 Boehringer Ingelheim International Gmbh Process for preparing aminocrotonylamino-substituted quinazoline derivatives
ES2385613T3 (es) 2006-09-18 2012-07-27 Boehringer Ingelheim International Gmbh Método para tratar cánceres que portan mutaciones de EGFR
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
JP2012515184A (ja) 2009-01-14 2012-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大腸がんの治療方法
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient

Also Published As

Publication number Publication date
EP1981863A1 (en) 2008-10-22
PL1981863T3 (pl) 2013-03-29
CA2639936A1 (en) 2008-08-02
JP2009528981A (ja) 2009-08-13
CA2639936C (en) 2014-06-17
CY1113778T1 (el) 2016-07-27
US7960546B2 (en) 2011-06-14
US8067593B2 (en) 2011-11-29
US8188274B2 (en) 2012-05-29
US20090306378A1 (en) 2009-12-10
ES2397181T3 (es) 2013-03-05
EP1981863B1 (en) 2012-10-10
SI1981863T1 (sl) 2013-01-31
WO2007085638A1 (en) 2007-08-02
US20110207932A1 (en) 2011-08-25
JP5241513B2 (ja) 2013-07-17
PT1981863E (pt) 2012-12-07
US20110207929A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
DK1981863T3 (da) Fremgangsmåde til fremstilling af aminocrotonylaminosubtituerede quinazolinderivater
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2046767T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK2094676T3 (da) Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
DK2155838T3 (da) Fremgangsmåde til fremstilling af forgrenede carbonhydrider
DK1884507T3 (da) Fremgangsmåde til fremstilling af glycerol
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK2084174T3 (da) Fremstilling af ribofuranosylpyrimidinnukleotider
DK1981859T3 (da) Fremstilling af delmopinol
DK2114886T3 (da) Fremgangsmåde til fremstilling af visse substituerede sulfiliminer
DK2048941T3 (da) Fremgangsmåde til opdræt af rovmider
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
DK2029567T3 (da) Fremgangsmåde til frembringelse af benzopyran-2-ol-derivater
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK2213654T3 (da) Fremgangsmåde til fremstilling af 2-amino-5-brombenzamid derivater
DK1813678T3 (da) Fremgangsmåde til fremstilling af glycogen
DK2348064T3 (da) Fremgangsmåde til fremstilling af polyalkylenglycolderivater
CR10562A (es) Nuevos derivados de piridazina
DK3106873T3 (da) Fremgangsmåde til detektering af cancer
DK2021309T3 (da) Fremgangsmåde til fremstilling af methanol
DK3214083T3 (da) Fremgangsmåde til fremstilling af quinolonforbindelser
DK2146944T3 (da) Fremgangsmåde til fremstillingen af 18f-mærkede folater
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
DK2079843T3 (da) Fremgangsmåde til fremstilling af biogas